Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 8:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 82 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Zolpidem tartrate Clear all
Completed Not applicable Interventional Results available

Zolpidem CR and Hospitalized Patients With Dementia

NCT00814502
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Dementia, Vascular, Sleep Disorders, Circadian Dysregulation
Interventions
Zolpidem CR, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2017 · Synced Sep 20, 2026, 8:10 AM EDT
Completed Not applicable Interventional Results available

The Role of Partial Reinforcement in the Long Term Management of Insomnia

NCT00662155
View directory record Official record
Conditions
Primary Insomnia
Interventions
Zolpidem, Placebos
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 55 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2017 · Synced Sep 20, 2026, 8:10 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of Adipiplon, Placebo and an Active Control in Primary Insomniacs

NCT00683436
View directory record Official record
Conditions
Primary Insomnia
Interventions
Adipiplon, Placebo, Ambien CR
Drug
Lead sponsor
Neurogen Corporation
Industry
Eligibility
21 Years to 64 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
9
States / cities
Pembroke Pines, Florida • South Miami, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2008 · Synced Sep 20, 2026, 8:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Chronic Hypnotic Use 2

NCT02456532
View directory record Official record
Conditions
Chronic Insomnia
Interventions
placebo, Zolpidem CR, Eszopiclone
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Sep 20, 2026, 8:10 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Positron Emission Tomography Assessment of the Central Nervous System Effects of Eszopiclone and Zolpidem

NCT00781482
View directory record Official record
Conditions
Healthy
Interventions
eszopiclone, zolpidem, placebo
Drug
Lead sponsor
Kettering Health Network
Other
Eligibility
18 Years to 35 Years · Male only
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Sep 20, 2026, 8:10 AM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Imaging the Effects of Zolpidem and Alprazolam in Healthy Volunteers at 3T

NCT01747590
View directory record Official record
Conditions
Psychotropic Drugs Effects
Interventions
Zolpidem, Alprazolam, Caffeine, Placebo
Drug · Other
Lead sponsor
Mclean Hospital
Other
Eligibility
21 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Sep 20, 2026, 8:10 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

The Role of Sleep in the Treatment of Cannabis Use Disorders

NCT01685073
View directory record Official record
Conditions
Drug Addiction
Interventions
Zolpidem extended-release, MET/CBT
Drug · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Sep 20, 2026, 8:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Crossover Study to Evaluate the Effect of Lemborexant Versus Placebo and Zolpidem on Postural Stability, Auditory Awakening Threshold, and Cognitive Performance in Healthy Subjects 55 Years and Older

NCT03008447
View directory record Official record
Conditions
Healthy Subjects
Interventions
LEM5, LEM10, ZOL, PBO
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
55 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
4
States / cities
Atlanta, Georgia • New York, New York • Raleigh, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Sep 20, 2026, 8:10 AM EDT
Completed Phase 4 Interventional

Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)

NCT04014387
View directory record Official record
Conditions
Progressive Supranuclear Palsy(PSP), Insomnia
Interventions
Suvorexant, Zolpidem, Placebo oral capsule
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 20, 2026, 8:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Impact of GABA-Enhancing Agents on Cortical GABA Concentrations Across the Menstrual Cycle in Women

NCT00676026
View directory record Official record
Conditions
Healthy
Interventions
Fluoxetine, Zolpidem, Progesterone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Sep 20, 2026, 8:10 AM EDT
Completed Phase 2 Interventional Results available

An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia

NCT00784875
View directory record Official record
Conditions
Primary Insomnia, Secondary Insomnia
Interventions
LY2624803, Placebo, zolpidem
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
49
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Sep 20, 2026, 8:10 AM EDT
Completed Phase 3 Interventional Results available

SM-1 vs 2 Comparators and Placebo in Participants With a History of Transient Insomnia.

NCT03331042
View directory record Official record
Conditions
Transient Insomnia
Interventions
SM-1, D+Z, D+L, Placebo
Drug
Lead sponsor
Sequential Medicine Ltd
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Sep 20, 2026, 8:10 AM EDT
Completed Phase 4 Interventional Results available

Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients

NCT00086281
View directory record Official record
Conditions
Obstructive Sleep Apnea Syndrome
Interventions
Xyrem (X), Zolpidem (Z), Modafinil (M), Placebo (P)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2012 · Synced Sep 20, 2026, 8:10 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Psilocybin Therapy for Chronic Low Back Pain

NCT05351541
View directory record Official record
Conditions
Chronic Low-back Pain
Interventions
Psilocybin therapy with Zolpidem and Modafinil, Psilocybin therapy with Zolpidem, Psilocybin therapy with Modafinil, Psilocybin therapy with Placebo
Drug
Lead sponsor
Joshua Woolley, MD, PhD
Other
Eligibility
25 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 20, 2026, 8:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep

NCT00893269
View directory record Official record
Conditions
Marijuana Dependence
Interventions
eszopiclone, Placebo, ramelteon, zolpidem
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Sep 20, 2026, 8:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Sedative-Anxiolytic Effects on Simulated Driving Performance

NCT03297944
View directory record Official record
Conditions
Psychomotor Impairment
Interventions
Alprazolam 2mg (2ALP/PLC), Alprazolam 1mg (1ALP/PLC), Alprazolam 0.5mg (0.5ALP/PLC), Zolpidem 10mg (ZOL/PLC), Placebo (PLC/PLC), Alprazolam 1mg (PLC/ALC)
Drug
Lead sponsor
Marion Coe
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Sep 20, 2026, 8:10 AM EDT
Completed Phase 1Phase 2 Interventional

Single Dose Pharmacokinetic and Pharmacodynamic Evaluation of Three Different Doses of Zolpidem in Children

NCT00494468
View directory record Official record
Conditions
Insomnia, Sleep Disorder
Interventions
Zolpidem
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
2 Years to 18 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
11
States / cities
Little Rock, Arkansas • La Jolla, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2007 · Synced Sep 20, 2026, 8:10 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Lavender vs Zolpidem Sleep Quality During Diagnostic PSG

NCT04102345
View directory record Official record
Conditions
Sleep
Interventions
Lavender Aromatherapy, Zolpidem
Other · Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Maplewood, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Sep 20, 2026, 8:10 AM EDT
Completed Phase 3 Interventional

Efficacy, Safety, and Tolerability of Ambien (Zolpidem) in the Treatment of Children Ages 6 to 17 With Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia

NCT00318448
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Zolpidem (SL800750)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 17 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 6, 2009 · Synced Sep 20, 2026, 8:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Safety and Efficacy of Chronic Hypnotic Use

NCT01006525
View directory record Official record
Conditions
Primary Insomnia
Interventions
zolpidem
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
21 Years to 70 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 6, 2011 · Synced Sep 20, 2026, 8:10 AM EDT
Recruiting Phase 2 Interventional

Trial of Zolpidem for Sleep in Children With Autism

NCT05540574
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder
Interventions
Zolpidem, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
8 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 20, 2026, 8:10 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Next-Dose Transition From Zolpidem to Lemborexant (LEM) for the Treatment of Insomnia

NCT04009577
View directory record Official record
Conditions
Insomnia
Interventions
LEM 5 mg, LEM 10 mg
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
17
States / cities
Glendale, Arizona • Sacramento, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Sep 20, 2026, 8:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Assess the Effect of Zolpidem, Silenor & Placebo on Arousability, Ataxia/Balance & Cognition in Healthy Volunteers

NCT02353299
View directory record Official record
Conditions
Healthy
Interventions
Silenor 6 mg, zolpidem 10 mg, Placebo
Drug
Lead sponsor
Currax Pharmaceuticals
Industry
Eligibility
21 Years to 50 Years · Male only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Novi, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 1, 2018 · Synced Sep 20, 2026, 8:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Estrogen for Treating Depression in Menopausal Women With Hot Flashes and Insomnia

NCT00227942
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders, Depression
Interventions
Estrogen Replacement Therapy, Zolpidem, placebo
Drug
Lead sponsor
Hadine Joffe, MD
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2014 · Synced Sep 20, 2026, 8:10 AM EDT